First I would like to say something of the development of knowledge of this disease. Credit for the first description is usually given to Erb who reported three cases in 1879 and to Goldflam who wrote a more comprehensive account in 1893, and the condition has sometimes been called the Erb-Goldflam disease. The present name was given to it by Jolly in 1895 who called it myasthenia gravis pseudo-paralytica. However, descriptions. of cases had appeared before Erb. In 1672 a book by Thomas Willis was published in Oxford entitled 'De Anima Brutorum'. Fortunately for some of us, an English translation was published in London eleven years later under the very literal title 'Two Discourses concerning the Soul of Brutes'. As Guthrie (1903) and Keynes (1961) have pointed out, myasthenia gravis is described in this book. In a section on 'the habitual and spurious palsies' we read:
'Nevertheless, those labouring with a want of spirits, who will exercise local motions as well as they can, in the morning are able to walk firmly, to fling about their arms hither and thither, or to take up any heavy thing, before noon the stock of Spirits being spent, which had flowed into the Muscles, they are scarce able to move Hand or Foot'.
Willis continues:
'At this time I had under my charge a prudent and honest Woman, who for many years hath been obnoxious to this sort of spurious Palsie, not only in the members, but also in her tongue: she for some time can speak freely and readily enough, but after 'Requests for reprints may be sent to: St Bartholomew's Hospital, London ECIA 7BE she has spoken long, or hastily, or eagerly, she is not able to speak a word but becomes mute as a Fish, nor can she recover the use of her voice under an hour or two'.
There then seems to be a gap of about two hundred years until there appeared an article by Samuel Wilks (1877) on 'cerebritis, hysteria and bulbar paralysis' in which he describes a girl who had an unexplained squint, general weakness and great difficulty in speaking. After a month she became much worse with very indistinct speech, dysphagia and inability to cough. She died with respiratory paralysis and at postmortem no pathological changes were found in the medulla. This paper preceded that of Erb by two years.
After the papers by Erb and Goldflam a few isolated case reports appeared in this country but attention was focused on the disease here by Campbell & Bramwell (1900) . They reviewed the 60-70 published case reports, including 9 of their own from the National Hospital. This is a superb paper and little has since been added to their clinical description of myasthenia gravis. They mention the absence of pathological changes and in an analysis of the possible cause of the disease they suggest that the seat of the disease is probably the motor end fibre or end-plate, and that this is probably affected by a toxic substance reaching it from the bloodstream.
Therapy, however, lagged behind. The first hope came from Tucson, Arizona in 1930 when Dr Harriet Edgeworth (1930 Edgeworth ( , 1933 , who had suffered from myasthenia gravis for six years, gave herself ephedrine in an effort to relieve menstrual cramps. She noted improvement in her muscle strength and three years later wrote that ephedrine continued to help her myasthenia. At times ephedrine had been omitted, sometimes without the patient knowing, and weakness increased within 48 hours.
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The major break-through came on 2 June 1934 when a letter appeared in The Lancet from Dr Mary Walker, AMO at St Alfege's Hospital, Greenwich. Acting on the idea that in myasthenia there might be a curare-like poisoning of the motor nerve endings or myoneural junctions, she gave an injection of gr. 1/60 (1.0 mg) of physostigmine with remarkable improvement in muscle power which lasted for 2-4 hours. With gr. 1/50 there was greater and longer lasting improvement. Larger doses cause unpleasant side-effects. It was in this short letter that this major advance in treatment was reported. Viets called it 'the miracle of St Alfege'. Later in the year Dr Walker showed to the Clinical Section of this Society a patient in whom she used the newly synthesized drug Prostigmin (neostigmine) in a dose of 2.5 mg with even better results, and this has since been the standard drug, as it causes fewer side-effects than physostigmine.
This discovery came at a particularly appropriate time as it was in the same year that Dale & Feldberg (1934) demonstrated that acetyl choline was liberated at the myoneural junctions in voluntary muscles and that its action was inhibited by the enzyme, cholinesterase.
The next major advance came from a quite different direction, the introduction of intermittent positive pressure respiration by Lassen (1953) during the poliomyelitis epidemic in Copenhagen in 1952. This method of mechanical respiration has been of the greatest value in the management of myasthenic crises, especially those associated with respiratory infections and also in the postoperative care of patients who have had thymectomy. I propose to discuss the association of myasthenia and thymic pathology later.
In 1960 Simpson put forward new views on the etiology of the disease, suggesting that it is an 'autoimmune' response of muscle in which an antibody to end-plate protein may be formed. Bartholomew's Hospital, 1946-72 for allowing me to include these cases in this series. There were 237 patients, 94 men and 143 women (Table 1) . This female predominance is the same as in other series. A thymoma was demonstrated in 59 patients and I will discuss this group later.
Age and sex incidence: The disease can start at any age (Fig 1) . In 7 of these patients symptoms occurred before the age of 10, and 6 started over the age of 70, the oldest being a woman whose first symptoms occurred at the age of 82. The main incidence of onset, however, is between the ages of 20 and 40 with a definite decrease of new cases after that age. In general the disease starts at a later age in men than in women, and there were only 7 men as compared with 38 women who started symptoms below the age of 20. The patients who did not have a thymoma (Fig 2) are similar to the overall group, but show fewer patients in the older age groups, which is when myasthenia in association with a thymoma is more likely to occur (Fig 3) . There was one example of familial myasthenia in the series, two sisters being affected, one first at the age of 19 and the other at 23. A number of instances of more than one member of a family being affected have been described in the literature (Namba 
Associated Disorders
In view of the possible autoimmune etiology of myasthenia, it is of some interest to note the occurrence of other disorders in which this etiology has been suggested ( Table 2 ). All these conditions have previously been recorded with myasthenia gravis. In this small number of cases there was no obvious time relationship between development of the disorders. For example, one woman developed rheumatoid arthritis six months after thymectomy when she had no clinical evidence of myasthenia. One patient had developed pernicious anaemia some years before the first symptoms of myasthenia and in another true myasthenia preceded the anemia by several years.
Thyroid disease: The occurrence of thyroid disease in association with myasthenia gravis has been recognized for many years, in particular hyperthyroidism. Sahay et al. (1965) from New End Hospital reported 5 cases of hypothyroidism and 3 of hyperthyroidism amongst 260 myasthenic patients. In my series thyroid tests have been performed only in patients suspected clinically of thyroid disorder: hyperthyroidism was found in 6, hypothyroidism in 2, and nontoxic goitre in 5. At one time it was suggested (MacLean & Wilson 1954) that there was a 'see-saw' relationship between hyperthyroidism and myasthenia, meaning that if the hyperthyroidism was adequately treated the myasthenia would become worse. This has not been evident in my six cases: each disease should be treated on its own merits.
The term myasthenia gravis is not entirely satisfactory. For the linguistic purist the Greek Table 2 Associated diseases of possibly autoimmune nature Diabetes mellitus 5 derivation of myasthenia with a Latin adjective attached may be disturbing, and the clinician realizes that there are cases to which the word gravis should not be applied. The best example of this is benign ocular myasthenia.
Benign Ocular Myasthenia Ocular symptoms, ptosis and double vision are the commonest presentation of myasthenia, in this series in 50 % of the patients. The remainder presented with bulbar or limb involvement in about equal numbers. Ferguson (1962) emphasized the importance of benign ocular myasthenia. In his series of 145 patients there were 50 in whom the disease was confined to the ocular muscles over a long period and he suggested that if there has been no spread from ocular to other muscles within three to five years there is a very good chance of the condition remaining ocular.
The proportion of such cases in this series is much smaller but 13 patients have a history of purely ocular symptoms for over 5 years; there are 11 males and 2 females, with onset under age 40 in 7 and over age 40 in 6. In all there has been a good response to edrophomium (Tensilon) or neostigmine in the earlier stages and I think that an ocular myopathy can be excluded. In some there was also some weakness of orbicularis oculi. Remissions and relapses are common in this group of patients and remission may occur after a long period of disability. For example, a man developed ocular myasthenia at the age of 59 and four years later had a complete remission which has lasted for the following twelve years.
I agree with Ferguson's generalization about benign ocular myasthenia but there are exceptions to it, as in the case of a man who developed ocular symptoms at the age of 65, the limb muscles becoming involved after eight years and, later still, the bulbar muscles. One patient (not included in the figures) appears to have had spread to other muscles after more than 20 years. This was a woman of 29 who four days after the birth of her first child developed weakness of the legs and difficulty in sitting up from lying, followed by difficulty in chewing and swallowing. At the age of 6 she had been in the National Hospital, having been noted to have bilateral ptosis and difficulty in moving her eyes at the age of 1 year. At that time, in addition to bilateral ptosis, the ocular movements were practically absent. There was also weakness of orbicularis oculi. After a neostigmine injection it was noted that the ptosis was less and there was some ability to move the eyes. There was controversy about the diagnosis, some observers considering it to be myasthenia, others a nuclear or supranuclear ophthalmoplegia. When I saw her at the age of 29 there was marked bilateral ptosis, gross restriction of all 9 765 ocular movements, weakness of orbicularis oculi, weakness of shoulder and hip girdle muscles and she was unable to sit up from lying without using her arms. After a Tensilon injection there was marked recovery of power in the limb and trunk muscles, improvement in the ptosis but no improvement in ocular movements. Over the last three years on regular neostignine she has remained largely free of muscle weakness but there is still moderate ptosis and virtually no ocular movements. There is no doubt about the diagnosis of myasthenia now, and it is difficult to believe that the ocular involvement noted at the age of 6 or earlier was not of similar nature.
Benign Non-remitting Myasthenia There are also cases of more generalized myasthenia which pursue a benign course. I am not here referring to patients who have remissions of the disease, sometimes for long periods, but to patients who continue with mild myasthenia well controlled by small doses of cholinergic drugs. I have followed 7 examples of this type of the disease for over ten years, 3 men and 4 women; in 3 the disease started before age 40 and in 4 after 40.
Even in patients with this type of the disease sudden worsening may occur in special circumstances, as shown by a woman who attended St Bartholomew's in 1939 at the age of 48 complaining of ptosis, double vision and fading of her voice. After a neostigmine test a diagnosis of myasthenia gravis was made by Dr Denny-Brown. She continued to attend at intervals until her death at the age of 74 of a cerebral infarct. All this time she had well controlled mild myasthenia. In 1956, however, she had a resection of the sigmoid colon for carcinoma and later developed a benign stricture of the colon. In September 1959 she was unfortunately given an enema and immediately afterwards had a myasthenic crisis with respiratory distress and had to be respired for the rest of the day. Following this the myasthenia resumed its benign course. This episode emphasizes the dangers of giving an enema to a myasthenic patient, as Keynes had earlier pointed out.
THE THYMUS
The first report of the association of a thymic tumour with myasthenia was by Laquer & Weigert in 1901 . Farquhar Buzzard (1905 studied the pathology of 5 fatal cases of myasthenia and, in addition to describing lymphorrhages in the skeletal muscles, he made a careful study of the thymus. In one case there was a very large thymus which had undergone changes partly proliferative and partly degenerative in nature (this sounds like a thymoma with necrosis in it) and in 2 others he reported simple hypertrophy of the gland. From then on there were a number of reports of thymic tumours in myasthenic patients and in 1939 Blalock et al. reported on a patient from whom a cystic thymic tumour had been removed in May 1936, with remarkable improvement in her myasthenia. In 1957 she was well and active except for minor myasthenic relapses following an accident and general surgery (Viets & Schwab 1960) .
In the present series diagnosis has been confirmed histologically in 37 cases. In the other 22 there has been radiological evidence of a mass in the anterior mediastinum in a patient suffering from myasthenia gravis. We have missed one tumour radiologically, a small tumour being found unexpectedly at thymectomy. We have not yet employed the more specialized techniques of pneumomediastinography or venography of the great vein of Keynes (Kreel 1969) .
In this series 59 patients (25 Y.) had a thymoma. This is an unusually high proportion, due to case selection: a number of patients known to have a tumour have been referred with a view to radiotherapy. Other series suggest that thymomas occur in about 15 % of myasthenic patients (Viets & Schwab 1960) .
Myasthenia associated with a tumour was equally frequent in men and women in contrast to the female predominance in the series as a whole. The onset of myasthenic symptoms was usually between the ages of 30 and 60, the youngest being a woman of 22. There are a few younger patients described; in fact Blalock's famous patient started to have symptoms at the age of 15. In general, myasthenia associated with a thymoma is severe and progressive but, as with everything else in myasthenia, there are many exceptions and such patients may have remissions or the disease may be mild and localized, as in a man of 53 with a month's history of ptosis and diplopia responding to neostigmine. He had no other muscle weakness but was found to have a calcified tumour in the anterior mediastinum. He had radiotherapy to the tumour and remained with only slight ptosis until his death from left ventricular failure eight years later. The best method of treatment of a thymoma in a myasthenic patient is controversial. Geoffrey Keynes (1954 Keynes ( , 1955 pointed out the unsatisfactory results of primary surgical removal. In 1967 Dr Hale and Professor Scowen published a monograph on thymic tumours based on cases from St Bartholomew's Hospital and a large number of the patients in their series are included in mine. They considered that the primary treatment should be radiotherapy to the tumour and that subsequent removal of the thymus and thymoma was not usually indicated. It is indeed difficult to draw a reliable conclusion from these cases but I consider that operation is indicated if the myasthenia has not improved within a year or so of radiotherapy.
In general, whichever method is used, radiotherapy alone or radiotherapy followed by operation, the prognosis for patients who have a thymoma is worse as regards the myasthenia than in patients without a tumour. However, occasional patients have a long remission after treatment; for example, a woman of 37 admitted in 1954, with a five-month history of generalized myasthenia and X-ray evidence ofa mass in the anterior mediastinum, had radiotherapy and one year later was off drugs and symptom free; sixteen years later there had been no recurrence of myasthenia.
The association of a thymoma and myasthenia gravis presents many other problems. It is well recognized that a tumour may be present for a considerable time before myasthenia develops; in fact Lattes (1962) describes the case of a man of 49 with an eight-month history of myasthenia who was known to have had a mediastinal mass for 21 years. The tumour was removed and was a thymoma of predominantly epithelial type. I have, however, found no previous description of a phenomenon which occurred in 2 patients in this series: a myasthenic patient going into complete remission and some years later developing evidence of a thymoma without any relapse of myasthenia.
The first patient was a man of 46 who was admitted under Dr Graham Hayward in March 1967 with a three-month history of superior vena cava obstruction and X-ray evidence of a mediastinal mass. Seven years earlier this man had developed ptosis, diplopia and difficulty with speech and chewing. He was seen at the National Hospital, Queen Square, and showed a dramatic response to edrophonium (Tensilon). Chest X-rays and tomograms showed no evidence of a mediastinal mass. He was treated with neostigmine and pyridostigmine and within a year there was a complete remission and he stopped the drugs. On admission to St Bartholomew's there was no clinical evidence of myasthenia. The mediastinal mass was explored by Mr I M Hill and it was invading the upper lobe of the lung and extending on to the pericardium. A biopsy showed it to be a thymoma. He had radiotherapy.
Six years later he developed a hemorrhage and pericardial effusion thought to be due to involvement by the thymoma, but still there was no recurrence of the myasthenia.
The second case was perhaps even more striking. This was a woman of 46 admitted in July 1962 with a three-month history of myasthenia involving ocular, bulbar and neck muscles.
There was no radiological evidence of a thymoma. She gradually improved while taking cholinergic drugs and by March 1965 she was off drugs and free of symptoms. In July 1971 she developed influenza and following this her doctor had a mass X-ray taken. She was readmitted and had no symptoms or signs of myasthenia and the chest X-ray gave a typical appearance of pleural seeding from a thymoma. We decided against further treatment at this stage but in May 1972 she had slight stridor and dyspncea and her lung function tests were deteriorating. A thoracotomy was carried out by Mr Hill and several large masses on the perietal pleura were palpable and, in addition to those shown on the X-ray, there were numerous small deposits. The lung was dissected off the mass palpable in the anterior mediastinum. A biopsy was taken from this mass and showed a lympho-epithelioma of the thymus. She was given radiotherapy to the thymoma and left hemi-thorax. In April 1973 there had been no real change in the chest pictures. She had at this time been free of myasthenia for over seven years.
Thymectomy
Removal of the nonneoplastic thymus in myasthenic patients was first carried out by Blalock, who in 1941 operated on 6 patients of whom three showed immediate improvement; in 1944 he reported on 20 patients of whom 13 had shown satisfactory improvement.
The first thymectomy for myasthenia in this country was performed by Mr Geoffrey Keynes in February 1942 on a patient of Dr E A Carmichael. This woman, then aged 31, had severe generalized myasthenia and she improved rapidly after operation. For the last six years she has been under my care. She remained well from 1943 until 1963 when, following pneumonia, she developed a mild recurrence of myasthenia which has persisted but is fairly well controlled by neostigmine. She has also had a recurrence of thyrotoxicosis treated by radioiodine, diabetes mellitus, and evidence of systemic lupus erythematosis. In spite of all this, and also severe cervical and lumbar spondylosis, she still works hard at the age of 62.
In 1942 Carson & Keynes presented the first results of thymectomy to a meeting of this Section; 12 patients had been operated on in the preceding nine months, three of whom were completely well, and there had been three postoperative deaths.
From an early stage Keynes (1954) pointed out that the results of operation in patients with thymic tumours must be assessed separately from those without tumours, as the results were considerably worse in the tumour patients. This distinction was not made in some of the earlier reports from the United States, which made comparative assessment of results difficult.
In 1958 Simpson published a statistical follow up of all Keynes's thymus operations, together with a few done by others. This comprised 258 nontumour cases. He attempted to compare the results with 99 nontumour cases treated medically at the National Hospital. One difficulty in the comparison was that the medically treated cases were largely treated between 1934 and 1941 and the operative cases were, of course, all after 1942. His general conclusions were that when tumour cases were excluded, significantly fewer women died of myasthenia if their thymus was removed than would be expected if they were treated with neostigmine alone, and that the number of women who were very greatly improved ten or more years after the onset of the disease was also significantly greater after thymectomy. Similar trends were found in the smaller number of male patients. In general the best results were obtained with a younger age of onset and a shorter preoperative duration of the disease. Henson and his colleagues reported on thymectomies at the London Hospital between 1948 and 1962. There were 28 nontumour cases, only 2 of whom were men. There was complete remission of myasthenia in 15 patients and considerable improvement in 5.
I have not done a full follow up of the patients operated on by Sir Geoffrey Keynes who are included in Simpson's follow up. Since his retirement the operation has been carried out by Mr D F Ellison Nash or Mr 0 S Tubbs. The operation has been done in a selected group of patients, people of either sex under the age of 45 in whom a thymoma has not been demonstrated radiologically, in whom the disease is progressive and not localized to the ocular muscles, and in (Table 3) . These are probably rather less accurate than the modifications used by Simpson and Henson but I have found them easier to apply. These results (Table 3) are not as impressive as those in the London Hospital series, but I consider that the operation is well worth while in the type of patient I have mentioned, although it is not possible at present to predict with any certainty before operation which patients are likely to benefit, and in those who do benefit improvement is usually slow over two to three years or longer. Once a patient has gone into a complete remission following operation a serious relapse is rare.
USE OF ACTH
In 1951 Torda & Wolff reported giving ACTH to 15 myasthenic patients, using a short course of 25 mg six hourly for five days. There was a partial remission of symptoms in 10, but they found that increase of weakness occurred during the course of ACTH and one patient died on the third day of treatment.
I first used this treatment in 1961, but experience with the second patient treated was unfortunate. This was a woman of 48 with generalized myasthenia who had a thymectomy three years previously without notable benefit. We started her on 80 units daily ofACTH gel intramuscularly. Shortly after the third injection she developed severe respiratory distress and had to be intubated and given artificial respiration for the next week.
My courage failed and we did not continue her course of ACTH; in fact did not use it again until 1965.
Excluding this patient, we now have experience of 14 courses in 8 patients. The dosage has varied a little but was usually 80-120 units gel daily for two weeks, tailing off in the third week. The more recent patients have been given tetracosactrin (Synacthen) 1 mg daily for one week and on alternate days for the next two weeks. Potassium supplements are needed as there is a marked risk of hypokalemia. Two patients had a thymoma, 2 had previously had a thymectomy and 3 were having artificial respiration when the ACTH was given. All the patients had severe myasthenia, usually generalized and in all cases involving the bulbar muscles. The most dramatic effect is the deterioration which occurs from the second to the fourth day of the course, usually lasting 3-4 days, and this occurred in 9 patients; improvement then starts. Five patients not previously on artificial respiration needed it for a few days on account of this deterioration.
In 2 cases there was no improvement following the ACTH and these patients did not show an initial deterioration. In 12 cases there was definite improvement: in 2 of these the partial remission only lasted 2-3 weeks but the average period of improvement was from 4 to 9 months. One patient had a useful remission for three years. These results (Table 4 ) are similar to those reported by others. Ossermann & Gakins (1966) reported considerable improvement in 8 of 11 patients and noted that all required artificial respiration during treatment. In this country Gibberd and colleagues (1971) reported on 9 patients given rather smaller doses of ACTH: in 8 there was marked improvement lasting many weeks or occasionally months; artificial respiration was needed in 4 on account of deterioration early in the treatment. Liversedge (1971) states that initial deterioration is less likely to occur if the sodium intake is restricted.
It is clear that this treatment must only be given in a hospital where assisted respiration is immediately available. In spite of its problems, I consider that it is worthwhile using in the small group of severely incapacitated myasthenics as there is a reasonable chance of bringing on a worthwhile remission which may last for months or longer. The way in which it acts in myasthenia is unknown. There has been considerable controversy about the nature of the disorder of function at the myoneural junction in myasthenia but the elegant work of Elmquist et al. (1964) suggests strongly that the defect is presynaptic and that there is a deficiency in the amount of acetylcholine in the quanta of transmitter released from the motor nerve terminals.
The etiology of the disease remains uncertain. In recent years much work has been done on the immunological aspects, on the hypothesis that it may be an autoimmune disease. I am not competent to evaluate this work but it seems clear that this etiology is by no means proved.
In conclusion, I should like to return to 'De Anima Brutorum', for after giving the clinical description referred to earlier Willis makes his own suggestions as to the cause. He writes: 'in this kind of spurious palsie arising from the defect, or rather, the weakness of the Animal Spirits, it may be suspected that not only the Spirits themselves are in fault, but besides, that sometimes the imbecility and impotency of local motion doth in some measure also depend upon the fault of the explosive copula suffused everywhere from the blood into the moving fibres.' If the modern terms myoneural junction or synaptic vesicles are substituted for the eloquent expression 'explosive copula' it is clear that Willis was very near present day views on the nature of the disturbance of function in myasthenia gravis.
